Search Results
117 results found-
We price program sponsor and donor to the WFH's Global Alliance for Progress (GAP) Program, 1,200 130 Furthermore, across our key products fairly to reflect their value a worldwide initiative seeking to save and improve the quality of life of people with the number ofto patients.
https://www.csl.com/-/media/csl/corporate-responsibility-reports/csl-limited-corporate-responsibility-report-2018.pdf -
Haemophilia and AFSTYLA Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Cyprus, Czech Republic, Denmark, Estonia, coagulation products Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Support and enhance plasma products and develop a novel Sweden, Switzerland, UK recombinant portfolio with a focus on scientific product innovation and patient benefit HAEMATE® P Iraq, Tunisia, Uzbekistan
https://www.csl.com/-/media/csl/corporate-responsibility-reports/csl-limited-corporate-responsibility-report-2017.pdf -
ToVs solely related to over-the-counter medicines - ToVs excluded from the scope of the EFPIA Disclosure Code, such as informational and educational materials, items of medical utility, food and beverage, medical samples - Fees charged by logistics agencies assisting in organising travel and meetings -
https://www.csl.com/-/media/shared/documents/vifor-disclosures/methodological-notes/methodological-note-ireland-2021.pdf -
ToVs solely related to over-the-counter medicines - ToVs excluded from the scope of the EFPIA Disclosure Code, such as informational and educational materials, items of medical utility, food and beverage, medical samples - Fees charged by logistics agencies assisting in organising travel and meetings -
https://www.csl.com/-/media/shared/documents/vifor-disclosures/methodological-notes/methodological-note-romania-2021.pdf -
CSL Innovation Pty Ltd Australia 100 CSL Behring (Australia) Pty Ltd Australia 100 CSL Behring LLC USA 100 CSL Plasma Inc USA 100 CSL Behring GmbH Germany 100 CSL Behring AG Switzerland 100 CSL Behring Lengnau AG Switzerland 100 CSLB Holdings Inc USA 100 CSL Finance Plc UK 100 CSL Finance Pty Ltd Australia 100 CSL Behring Holdings Limited UK 100 CSL Behring (Holdings) Pty Ltd Australia 100 Seqirus UK Limited UK 100 Seqirus Pty Ltd Australia 100 Seqirus Vaccines Limited UK 100 Seqirus USA Inc USA 100 Seqirus Inc USA 100 Vifor Pharma Participations Ltd Switzerland 100 Vifor (International) Ltd Switzerland 100 Vifor Fresenius Medical Care Renal Pharma Ltd Switzerland 55 *
https://www.csl.com/-/media/one-csl/sustainability/data-and-reporting-centre/documents/csl-limited-tax-transparency-report-2022-23.pdf -
our subsidiary companies located in Australia, Germany, Switzerland, USA and the UK.
https://www.csl.com/-/media/csl/tax-transparency-reports/csl-limited-tax-transparency-report-2021.pdf -
CSL Innovation Pty Ltd Australia 100 CSL Behring (Australia) Pty Ltd Australia 100 CSL Behring LLC USA 100 CSL Plasma Inc USA 100 CSL Behring GmbH Germany 100 CSL Behring AG Switzerland 100 CSL Behring Lengnau AG Switzerland 100 CSLB Holdings Inc USA 100 CSL Finance Plc UK 100 CSL Finance Pty Ltd Australia 100 Seqirus UK Limited UK 100 Seqirus Pty Ltd Australia 100 Seqirus Vaccines Limited UK 100 Seqirus USA Inc USA 100 Seqirus Inc USA 100 *
https://www.csl.com/-/media/one-csl/sustainability/data-and-reporting-centre/documents/csl-limited-tax-transparency-report-2021-22.pdf -
ST. GALLEN, SWITZERLAND, March 28, 2024 / PRNewswire / -- CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months.
https://newsroom.csl.com/2024-03-28-Vafseo-R-approved-by-the-U-S-FDA-for-the-treatment-of-anemia-due-to-chronic-kidney-disease-in-dialysis-dependent-adult-patients -
Pricing of Intercompany Transactions In line with our Tax Policy, CSL has a robust transfer The majority of CSL's related party transactions are pricing policy and transfer pricing guidelines in between our subsidiary companies located in place that comply with the OECD transfer pricing Australia, Germany, Switzerland, USA and the UK.
https://www.csl.com/-/media/csl/tax-transparency-reports/csl-limited-tax-transparency-report-2019.pdf -
CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of...
https://newsroom.csl.com/csl-vifor